Advertisement

Le dépistage du cancer ovarien

  • P. Mathevet
Part of the Abord clinique book series (ONCOLPRAT)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Taylor KJ, Schwartz PE (2001) Cancer screening in a high risk population: a clinical trial. Ultrasound Med Biol 27(4): 461–66CrossRefPubMedGoogle Scholar
  2. 2.
    Hill C, Koscielnys S, Doyaon D, Benhamou E (1993) Évolution de la mortalité par cancer en France 1950–1990. Mise à jour 1986–1990. Éditions INSERM, ParisGoogle Scholar
  3. 3.
    Van Nagell JR (1991) Ovarian Cancer Screening. Cancer 68: 679–80PubMedGoogle Scholar
  4. 4.
    Salonne C, Jourdain O, Lefebvre C et al. (2004) Méthodes de dépistage du cancer de l’ovaire. In: Descamps P, Baldauf JJ, Bonnier P (ed) Dépistage des cancers gynécologiques et mammaires. Masson, Paris p 135–56Google Scholar
  5. 5.
    Zurawski VR, Orajaseter H, Andersen A et al. (1988) Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer 42: 677–80PubMedGoogle Scholar
  6. 6.
    Helzlsouer KJ, Bush TL, Alberg AJ et al. (1993) Prospective study of serum CA 125 levels as markers of ovarian cancer. JAMA 269: 1123–6CrossRefPubMedGoogle Scholar
  7. 7.
    Einhorn N, Sjovall K, Knapp RC et al. (1992) Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 80(1): 14–8PubMedGoogle Scholar
  8. 8.
    Jacobs IJ, Bast RC Jr (1989) The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 4(1): 1–12PubMedGoogle Scholar
  9. 9.
    Mac Donald ND, Jacobs IJ (1999) Is there a place for screening in ovarian cancer? Eur J Obstet Gynecol Reprod Biol 82: 155–7Google Scholar
  10. 10.
    Skates SJ, Xu FJ, Yu YH et al. (1995) Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 76(suppl. 10): 2004–10PubMedGoogle Scholar
  11. 11.
    Van Nagell JR Jr, Depriest PD, Reedy MB et al. (2000) The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 77(3): 350–6PubMedGoogle Scholar
  12. 12.
    Sato S, Yokoyama Y, Sakamoto T et al. (2000) Usefulness of mass screening for ovarian carcinoma using transvaginal sonography. Cancer 89: 582–8CrossRefPubMedGoogle Scholar
  13. 13.
    Higgins RV, Van Nagell JR, Donaldson ES et al. (1989) Transvaginal sonography as a screening method for ovarian cancer. Gynecol Oncol 34: 402–6CrossRefPubMedGoogle Scholar
  14. 14.
    Bourne TH, Campbell S, Reynolds KM et al. (1993) Screening for early familial ovarian cancer with transvaginal ultra-sonography and colour blood imaging. BMJ 306: 1025–9PubMedGoogle Scholar
  15. 15.
    Muto MG, Cramer DW, Brown DL et al. (1993) Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center. Gynecol Oncol 51: 12–20CrossRefPubMedGoogle Scholar
  16. 16.
    Weiner Z, Beck D, Shteiner M et al. (1993) Screening for ovarian cancer in women with breast cancer with transvaginal sonography and color flow imaging. J Ultrasound Med 12: 387–93PubMedGoogle Scholar
  17. 17.
    Vuento MH, Pirhonen JP, Makinen JI et al. (1995) Evaluation of ovarian findings in asymptomatic postmenopausal women with color doppler ultrasound. Cancer 76: 1214–8PubMedGoogle Scholar
  18. 18.
    De Priest PD, Gallion HH, Pavlik EJ et al. (1997) Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol 65: 408–14Google Scholar
  19. 19.
    Karlan BY, Platt LD et al. (1994) The Current Status of Ultrasound and Color Doppler Imaging in Screening for Ovarian Cancer. Gynecol Oncol 55: S28–S33CrossRefPubMedGoogle Scholar
  20. 20.
    Pavlik EJ, Van Nagell JR, De Priest PD et al. (1995) Participation in transvaginal ovarian cancer screening: compliance, correlation factors, and costs. Gynecol Oncol 57: 395–400CrossRefPubMedGoogle Scholar
  21. 21.
    Puls LE, Powell DE, De Priest PD, Gallion HH et al. (1992) Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol 47: 53–7CrossRefPubMedGoogle Scholar
  22. 22.
    De Priest PD, Shenson D, Fried A et al. (1993) A morphology index based on sonographic findings in ovarian cancer. Gynecol Oncol 51: 7–11Google Scholar
  23. 23.
    Kurjak A, Zalud I (1992) Transvaginal colour doppler in the differenciation between benign and malignant ovarian masses. In Sharp F, Mason WP, Creasman W, eds. Ovarian cancer. London, England, Chapman & Hall 249–64Google Scholar
  24. 24.
    Granberg S, Wikland M, Jansson L (1989) Macroscopic characterization of ovar-ian tumors and the relation to the histological diagnosis: criteria to be used for ultra-sound evaluation. Gynecol Oncol 35: 139–44PubMedGoogle Scholar
  25. 25.
    Sassone AM, Timor-Tritsch IE, Artner A et al. (1991) Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovariant malignancy. Obstet Gynecol 78: 70–6PubMedGoogle Scholar
  26. 26.
    Tailor A, Jurkovic D, Bourne TH et al. (1997) Sonographic prediction of malignancy in adnexal masses using multivariate logistic regression analysis. Ultrasound Obstet Gynecol 10: 41–7CrossRefPubMedGoogle Scholar
  27. 27.
    Bourne TH, Campbell S, Steer C et al. (1989) Transvaginal color flow imaging: a possible new screening technique for ovarian cancers. BMJ 299: 1367–70PubMedGoogle Scholar
  28. 28.
    Kurjak A, Zalud I, Jurkovic D et al. (1989) Transvaginal color Doppler assessment of pelvic circulation. Acta Obstet Gynecol Scand 68: 131–5PubMedGoogle Scholar
  29. 29.
    Kurjak A, Zalud I, Alfirevic Z (1991) Evaluation of adnexal masses with transvaginal color ultrasound. J Ultrasound Med 10: 295–7PubMedGoogle Scholar
  30. 30.
    Kurjak A, Shalan H, Kupesic S et al. (1994) An attempt to screen asymptomatic women for ovarian and endometrial cancer with transvaginal color and pulsed doppler sonography. J Ultrasound Med 13: 295–301PubMedGoogle Scholar
  31. 31.
    Carter JR, Lau M, Fowler JM et al. (1995) Blood flow characteristics of ovarian tumors: Implications for ovarian cancer screening. Am. J. Obstet Gynecol 172: 901–7CrossRefPubMedGoogle Scholar
  32. 32.
    Jain KA (1994) Prospective evaluation of adnexal masses with endovaginal gray-scale and duplex and color doppler US: Correlation with pathologic findings. Radiology 191: 63–7PubMedGoogle Scholar
  33. 33.
    Stein SM, Laifer-Narin S, Johnson MB et al. (1995) Differentiation of benign and malignant adenxal masses: Relative value of gray-scale, color doppler, and spectral doppler sonography. AJR 164: 381–6PubMedGoogle Scholar
  34. 34.
    Timor-Tritsch IE, Lerner J, Monteagudo A et al. (1992) Transvaginal sonographic characteristization of ovarian masses using color-flow directed doppler measurements. Ultrasound Obstet Gynecol 2(suppl): 171–6Google Scholar
  35. 35.
    Fleischer AC, Rodgers WH, Kepple DM et al. (1993) Color Doppler sonography of ovarian masses: a multiparameter analysis. J Ultrasound Med 12: 41–8PubMedGoogle Scholar
  36. 36.
    Schelling M, Braun M, Kuhn W et al. (2000) Combined transvaginal B-mode and color doppler sonography for differential diagnosis of ovarian tumors: results of a multivariate logistic regression analysis. Gynecol Oncol 77(1): 76–86CrossRefGoogle Scholar
  37. 37.
    Guerriero S, Alcazar JL, Ajossa S et al. (2001) Comparison of conventional color doppler imaging and power doppler imaging for the diagnosis of ovarian cancer: results of a european study. Gynecol Oncol 83(2): 299–304CrossRefPubMedGoogle Scholar
  38. 38.
    Cohen LS, Escobar PF, Scharm C et al. (2001) Three dimensional power doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol Oncol 82(1): 40–8CrossRefPubMedGoogle Scholar
  39. 39.
    Varras M (2004) Benfits and limitations of ultrasonographic evaluation of uterine adnexal lesions in early detection of ovarian cancer. Clin Exp Obst Gyn 31: 85–98Google Scholar
  40. 40.
    De Priest PD, De Simone CP (2003) Ultrasound screening for the early detection of ovarian cancer. J Clin Oncol 21: 194s–9sGoogle Scholar
  41. 41.
    Jacobs IJ, Davies AP, Bridges J et al. (1993) Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 306: 1030–4PubMedGoogle Scholar
  42. 42.
    Jacobs IJ, Skates SJ, Mac Donald N et al. (1999) Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 353: 1207–10CrossRefPubMedGoogle Scholar
  43. 43.
    Menon U (2004) Ovarian cancer screening. CMAJ 171: 323–4PubMedGoogle Scholar
  44. 44.
    Skates SJ, Menon U, Mc Donald N et al. (2003) Calculation of the risk of ovarian cancer from serial CA 125 values for preclinical detection in postmenopausal women. J Clin Oncol 2(10Suppl): 206–10Google Scholar
  45. 45.
    Menon U, Jacobs IJ (2001) Ovarian cancer screening in the general population: current status. Int J Gynecol Cancer 11(suppl1): 3–6PubMedGoogle Scholar
  46. 46.
    Nci: Current Clinical Trials in Oncology: http://cancernet.nci.nih.gov/cgi-bin/srchcgi.exeGoogle Scholar
  47. 47.
    Skates SJ, Horick N, Yu Y et al. (2004) Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol 22(20): 4059–66CrossRefPubMedGoogle Scholar
  48. 48.
    Saito M, Aoki D, Susumu N et al. (2005) Efficient screening for ovarian cancers using a combination of tumor markers CA602 and CA546. Int J Gynecol Cancer 15(1): 37–44CrossRefPubMedGoogle Scholar
  49. 49.
    Dupont J, Tanwar MK, Thaler HT et al. (2004) Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol 22(16): 3330–9PubMedGoogle Scholar
  50. 50.
    Kim JH, Skates SJ, Uede T et al. (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287(13): 1671–9CrossRefPubMedGoogle Scholar
  51. 51.
    Petricoin EF, Arkedani AF, Hitt BA et al. (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359: 572–7PubMedGoogle Scholar
  52. 52.
    Ott HW, Lindner H, Sarg B et al. (2003) Calgranulins in cystic fluid and serum from patients with ovarian carcinomas. Cancer Res 63: 7507–14PubMedGoogle Scholar
  53. 53.
    Chang HW, Lee SM, Goodman SN et al. (2002) Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst 94; 1697–703PubMedGoogle Scholar
  54. 54.
    Elit B (2001) Familial ovarian cancer. Can Fam Physician 47: 778–84PubMedGoogle Scholar
  55. 55.
    Eisinger F, Bressac B, Castaigne D et al. (2004) Identification et prise en charge des prédispositions héréditaires aux cancers du sein et de l’ovaire (mise à jour 2004). Bull Cancer 91(3): 219–37PubMedGoogle Scholar
  56. 56.
    Wooster R, Weber BL (2003) Breast and ovarian cancer. N Engl J Med 348: 2339–47CrossRefPubMedGoogle Scholar
  57. 57.
    Miki Y, Swensen J, Shattuck-Eidens D et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCAl. Science 266: 66–71PubMedGoogle Scholar
  58. 58.
    Lynch HT, Watson P, Bewtra C et al. (1991) Hereditary ovarian cancer: heterogeneity in age at diagnosis. Cancer 67: 1460–6PubMedGoogle Scholar
  59. 59.
    Crvenkovic G, Karlan BY, Platt LD (1996) Current rote of ultrasound in ovarian cancer screening. Clin Obstet Gynecol 39: 259–67CrossRefPubMedGoogle Scholar
  60. 60.
    Descamps P, Karlan BY (1997) The status of ultrasound and color Doppler imaging for the early detection of ovarian carcinoma. Cancer Invest 15(3): 265–9Google Scholar
  61. 61.
    Laframboise S, Nedelcu R, Murphy J et al. (2002) Use of CA-125 and ultra-sound in highrisk women. Int J Gynecol Cancer 12(1): 86–91CrossRefPubMedGoogle Scholar
  62. 62.
    Meiser B, Butow P, Barratt A et al. (1999) Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer. Gynecol Oncol 75(1): 122–9CrossRefPubMedGoogle Scholar
  63. 63.
    Rebbeck TR, Lynch HT, Neuhausen SL et al. (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346: 1616–22CrossRefPubMedGoogle Scholar
  64. 64.
    Powell CB, Kenley E, Chen LM et al. (2005) Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 23(1): 127–32PubMedGoogle Scholar
  65. 65.
    Scheuer L, Kauff N, Robson M et al. (2002) Out-come of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20(5): 1260–8CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag France 2006

Authors and Affiliations

  • P. Mathevet

There are no affiliations available

Personalised recommendations